Jyong Biotech (MENS) Competitors $62.00 +2.47 (+4.15%) As of 09/23/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsFDA EventsHeadlinesSEC FilingsShort InterestTrendsBuy This Stock MENS vs. GMAB, SMMT, RDY, ASND, VTRS, QGEN, BBIO, ROIV, ELAN, and VRNAShould you be buying Jyong Biotech stock or one of its competitors? The main competitors of Jyong Biotech include Genmab A/S (GMAB), Summit Therapeutics (SMMT), Dr. Reddy's Laboratories (RDY), Ascendis Pharma A/S (ASND), Viatris (VTRS), QIAGEN (QGEN), BridgeBio Pharma (BBIO), Roivant Sciences (ROIV), Elanco Animal Health (ELAN), and Verona Pharma PLC American Depositary Share (VRNA). These companies are all part of the "pharmaceutical products" industry. Jyong Biotech vs. Its Competitors Genmab A/S Summit Therapeutics Dr. Reddy's Laboratories Ascendis Pharma A/S Viatris QIAGEN BridgeBio Pharma Roivant Sciences Elanco Animal Health Verona Pharma PLC American Depositary Share Genmab A/S (NASDAQ:GMAB) and Jyong Biotech (NASDAQ:MENS) are both pharmaceutical products companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, valuation, media sentiment, analyst recommendations, risk, dividends, institutional ownership and profitability. Do analysts prefer GMAB or MENS? Genmab A/S currently has a consensus target price of $40.00, suggesting a potential upside of 39.23%. Given Genmab A/S's stronger consensus rating and higher probable upside, equities analysts plainly believe Genmab A/S is more favorable than Jyong Biotech.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Genmab A/S 1 Sell rating(s) 2 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 2.73Jyong Biotech 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Is GMAB or MENS more profitable? Genmab A/S has a net margin of 37.53% compared to Jyong Biotech's net margin of 0.00%. Genmab A/S's return on equity of 21.03% beat Jyong Biotech's return on equity.Company Net Margins Return on Equity Return on Assets Genmab A/S37.53% 21.03% 16.98% Jyong Biotech N/A N/A N/A Does the media refer more to GMAB or MENS? In the previous week, Jyong Biotech had 2 more articles in the media than Genmab A/S. MarketBeat recorded 8 mentions for Jyong Biotech and 6 mentions for Genmab A/S. Genmab A/S's average media sentiment score of 0.62 beat Jyong Biotech's score of 0.53 indicating that Genmab A/S is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Genmab A/S 1 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Jyong Biotech 3 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has stronger earnings & valuation, GMAB or MENS? Genmab A/S has higher revenue and earnings than Jyong Biotech. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGenmab A/S$3.12B5.90$1.14B$1.9914.44Jyong BiotechN/AN/AN/AN/AN/A Do institutionals and insiders hold more shares of GMAB or MENS? 7.1% of Genmab A/S shares are held by institutional investors. 1.5% of Genmab A/S shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. SummaryGenmab A/S beats Jyong Biotech on 11 of the 12 factors compared between the two stocks. Get Jyong Biotech News Delivered to You Automatically Sign up to receive the latest news and ratings for MENS and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding MENS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MENS vs. The Competition Export to ExcelMetricJyong BiotechPharmaceutical Preparations IndustryManufacturing SectorNASDAQ ExchangeMarket Cap$4.53B$873.85M$2.54B$10.50BDividend YieldN/A4.84%2.49%4.57%P/E RatioN/A1.2126.4526.62Price / SalesN/A116.80218.8291.77Price / CashN/A17.6451.2461.85Price / BookN/A6.4633.216.45Net IncomeN/A-$5.56M$14.12M$271.57M7 Day Performance15.43%0.53%0.62%2.61%1 Month Performance34.78%5.75%3.72%7.28%1 Year PerformanceN/A25.85%70.48%29.60% Jyong Biotech Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MENSJyong BiotechN/A$62.00+4.1%N/AN/A$4.53BN/A0.0031Gap DownHigh Trading VolumeGMABGenmab A/S3.5686 of 5 stars$27.99+0.6%$39.25+40.2%+19.0%$17.85B$3.12B16.272,682Analyst UpgradeSMMTSummit Therapeutics3.1619 of 5 stars$18.94flat$33.79+78.4%-12.6%$14.07B$700K-18.75110RDYDr. Reddy's Laboratories2.7472 of 5 stars$14.64-0.2%$16.95+15.8%-8.9%$12.24B$3.81B22.1727,811Positive NewsASNDAscendis Pharma A/S2.9825 of 5 stars$194.62-0.5%$244.36+25.6%+32.3%$11.97B$393.54M-37.721,017Positive NewsVTRSViatris1.2988 of 5 stars$9.60-3.6%$10.40+8.3%-16.3%$11.61B$14.74B-3.3132,000High Trading VolumeQGENQIAGEN4.3595 of 5 stars$45.39+0.2%$49.69+9.5%+5.5%$10.07B$1.98B26.825,765BBIOBridgeBio Pharma4.4959 of 5 stars$51.47+0.5%$63.94+24.2%+102.8%$9.79B$221.90M0.00400ROIVRoivant Sciences3.4248 of 5 stars$13.95-0.9%$17.67+26.6%+23.9%$9.61B$29.05M0.00860Trending NewsInsider TradeAnalyst RevisionELANElanco Animal Health2.5914 of 5 stars$18.63+0.5%$17.33-6.9%+28.5%$9.21B$4.44B21.669,000VRNAVerona Pharma PLC American Depositary Share2.0411 of 5 stars$106.37-0.1%$109.00+2.5%+259.0%$9.17B$42.28M-107.4430Positive News Related Companies and Tools Related Companies GMAB Alternatives SMMT Alternatives RDY Alternatives ASND Alternatives VTRS Alternatives QGEN Alternatives BBIO Alternatives ROIV Alternatives ELAN Alternatives VRNA Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MENS) was last updated on 9/24/2025 by MarketBeat.com Staff From Our PartnersWhat The Silver Boom Could Mean For You…AI, electric vehicles, and even global central banks are quietly fueling record demand for silver. This once-o...Goldco Precious Metals | SponsoredWarren Buffett’s #1 AI Stock: Not Mag 7, And NOT on the NasdaqNew Amazon Crisis Could Tank U.S. Stock Market A new panic is halting AI projects at Amazon and could split...Altimetry | SponsoredBuffett, Gates and Bezos Quietly Dumping Stocks—Here's WhyImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredIRS Wants Another Check on Sept 15th—What If You Could Keep It Instead?On September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | SponsoredTrump’s new nightmare beginsPorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredIs This Nvidia’s Next Big Invention? (Picture Inside)Nvidia gave investors a chance to make more than 150 times their money with its AI chips known as graphic proc...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Jyong Biotech Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Jyong Biotech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free MENS Stock Alerts